Overview

A Phase I, Open-Label, Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide in Healthy Chinese Participants

Status:
Recruiting

Trial end date:
2021-12-14

Target enrollment:

Participant gender:

Summary

A Phase I, single centre, open-label study to investigate the pharmacokinetics (PK), safety and tolerability of single and multiple twice daily doses of inhaled Aclidinium Bromide in healthy Chinese male and female subjects.

Phase:

Phase 1

Details

Lead Sponsor:

AstraZeneca

Treatments:

Bromides